{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T22:38:16Z","timestamp":1777934296623,"version":"3.51.4"},"reference-count":15,"publisher":"SAGE Publications","issue":"3","license":[{"start":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T00:00:00Z","timestamp":1514505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Oncol Pharm Pract"],"published-print":{"date-parts":[[2019,4]]},"abstract":"<jats:p>Mycotic aneurysms are a fatal manifestation of disseminated fungal infections in immunocompromised hosts. We present a patient with an Aspergillus mycotic aneurysm after hematopoietic cell transplant. Due to CYP2C19 rapid metabolizer phenotype (*1\/*17), therapeutic levels of voriconazole were unobtainable. Successful therapy was achieved with posaconazole salvage therapy and early, aggressive surgery. This case demonstrates the consequences of voriconazole rapid metabolism and the potential impact of genetic variants.<\/jats:p>","DOI":"10.1177\/1078155217748471","type":"journal-article","created":{"date-parts":[[2017,12,29]],"date-time":"2017-12-29T07:54:28Z","timestamp":1514534068000},"page":"703-705","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["The challenges of treating aspergillus abdominal aneurysm after hematopoietic cell transplant: Rapid voriconazole metabolizer"],"prefix":"10.1177","volume":"25","author":[{"given":"Justin A","family":"Wasko","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Minnesota Medical Center, Minneapolis, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celalettin","family":"Ustun","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Hematology-Oncology and Transplantation, University of Minnesota, Minneapolis, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Birkenbach","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rumi","family":"Faizer","sequence":"additional","affiliation":[{"name":"Department of Surgery, Division of Vascular Surgery, University of Minnesota, Minneapolis, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime S","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Medicine, Division of Infectious Diseases, University of Minnesota, Minneapolis, MN, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2017,12,29]]},"reference":[{"key":"bibr1-1078155217748471","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.146563"},{"key":"bibr2-1078155217748471","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2016.04.018"},{"key":"bibr3-1078155217748471","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.2018"},{"key":"bibr4-1078155217748471","unstructured":"xTAG\u00ae CYP2C19 Kit v3 [package insert]. Luminex Corporation, Austin, TX, 2013."},{"key":"bibr5-1078155217748471","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw326"},{"key":"bibr6-1078155217748471","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt508"},{"key":"bibr7-1078155217748471","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.31.5.540"},{"key":"bibr8-1078155217748471","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200241120-00002"},{"key":"bibr9-1078155217748471","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-016-2089-y"},{"key":"bibr10-1078155217748471","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-008-0574-7"},{"key":"bibr11-1078155217748471","doi-asserted-by":"crossref","unstructured":"Moriyama B, Obeng AO, Barbarino J, et\u00a0al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy.\n                      Clin Pharmacol Ther\n                      . Epub ahead of print 16 December 2016. DOI: 10.1002\/cpt.583.","DOI":"10.1002\/cpt.583"},{"key":"bibr12-1078155217748471","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-010-0914-2"},{"key":"bibr13-1078155217748471","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku529"},{"key":"bibr14-1078155217748471","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2015.05.002"},{"key":"bibr15-1078155217748471","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.32.2.267"}],"container-title":["Journal of Oncology Pharmacy Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217748471","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/1078155217748471","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1078155217748471","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T02:17:53Z","timestamp":1777688273000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1078155217748471"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,29]]},"references-count":15,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["10.1177\/1078155217748471"],"URL":"https:\/\/doi.org\/10.1177\/1078155217748471","relation":{},"ISSN":["1078-1552","1477-092X"],"issn-type":[{"value":"1078-1552","type":"print"},{"value":"1477-092X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,29]]}}}